IP Library Granted Patent US 10,046,017
Granted Patent B2
US 10,046,017 · App. 15/109,723 · Granted Aug 14, 2018

Pomegranate skin extract for treating fatty liver

Inventors: Ignatius Szeto (Beijing, CN); Peifang Zhang (Chesterfield, MO); Weiguo Zhang (Irving, TX); Junkuan Wang (Beijing, CN); Chieh Jason Chou (Chexbres, CH)
Assignee: Nestec S.A.
A61K36/185A23L33/105A23L33/30A61K9/0053A61K31/7048A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,046,017
App. No.
15/109,723
Granted
Aug 14, 2018
Kind
B2
Abstract

Use of a pomegranate skin extract for use in the treatment of metabolic syndrome, more particularly, fatty liver disease. More particularly, the pomegranate skin extract is used in inhibiting body weight gain in the prevention and/or the treatment of fatty liver disease in mammals.

Claims (10)

1. A method for inhibiting body weight gain and treating fatty liver disease in a human having the fatty liver disease and a characteristic selected from the group consisting of (i) a body mass index equal to or above 25, (ii) the fatty liver disease is non-alcoholic fatty liver disease, and (iii) a combination thereof, the method comprising administering a composition comprising pomegranate skin extract to the human.

2. The method of claim 1 , wherein the composition comprises at least 30% of punicalagin.

3. The method of claim 1 , wherein the composition is administered in an amount that inhibits inhibiting steatosis.

4. The method of claim 1 , wherein the composition is administered in an amount that decreases the expression level of liver function markers ALT and AST.

5. The method of claim 1 , wherein the human has a high fat diet.

6. The method of claim 1 , wherein the human has a body mass index equal to or above 25.

7. The method of claim 1 , wherein the human is a patient suffering from non-alcoholic fatty liver disease.

8. The method of claim 1 , wherein the composition is administered orally.

9. The method of claim 1 , wherein the oral administration is performed via a route selected from the group consisting of foods, drinks, dietary supplements and pharmaceutical compositions.

10. The method of claim 1 , wherein composition is administered at a dose from 1 to 50 mg/kg/day.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2017
From: SZETO, IGNATIUS; ZHANG, PEIFANG; ZHANG, WEIGUO; WANG, JUNKUAN; CHOU, CHIEH JASON
To: NESTEC S.A.
Reel/Frame 043371/0968 →
Continuity (1)
Related Publication 20160324907A1 · Nov 10, 2016